Analytical Data
-
基因名
IL-23 Receptor
- Application
-
别名
SGRF;IL-23p19;CLMF p40;IL-12 subunit p40;NKSF2
-
种属
Human
-
表达系统
HEK293
-
标签
C- His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q9NPF7 & P29460
-
表达区间
20-189aa & 23-328aa
-
分子量
54.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The IL-23 receptor (IL-23R) is a critical component of the immune system, playing a pivotal role in the regulation of inflammatory responses and the pathogenesis of autoimmune diseases. It is specifically involved in mediating the effects of interleukin-23 (IL-23), a cytokine implicated in several inflammatory conditions, including psoriasis, inflammatory bowel disease, and ankylosing spondylitis. Research into IL-23R has escalated due to its potential as a therapeutic target; blocking this receptor could provide a new avenue for treating conditions driven by excessive inflammatory responses. Recombinant proteins, including IL-23R, are essential for elucidating the receptor's structure, function, and interactions with IL-23 and its downstream signaling pathways. These studies are crucial for understanding how IL-23R contributes to immune regulation and disease mechanisms. Furthermore, the development of IL-23R-blocking monoclonal antibodies has shown promise in clinical settings, underscoring the need for high-quality recombinant IL-23R for validation and testing in various assays. This growing interest in IL-23R has propelled a wave of scientific inquiry aimed at harnessing its therapeutic potential, highlighting the significance of advanced protein expression and purification methods to produce functional IL-23R for both basic research and clinical applications.
